Ascendis Pharma AS
$ 208.58
4.03%
04 Dec - close price
- Market Cap 12,250,181,000 USD
- Current Price $ 208.58
- High / Low $ 209.45 / 198.60
- Stock P/E N/A
- Book Value -2.85
- EPS -4.45
- Next Earning Report 2026-02-12
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.08 %
- ROE -8.18 %
- 52 Week High 223.19
- 52 Week Low 118.03
About
Ascendis Pharma A/S is a biopharmaceutical innovator based in Hellerup, Denmark, dedicated to creating transformative therapies for significant unmet medical needs in various therapeutic areas, particularly rare diseases and endocrine disorders. Leveraging its proprietary TransCon™ technology platform, the company is actively advancing a promising pipeline of product candidates through rigorous clinical trials. Ascendis is focused not only on developing groundbreaking treatments but also on establishing a sustainable business model that prioritizes patient health and supports long-term growth initiatives.
Analyst Target Price
$259.19
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-06 | 2025-08-07 | 2025-05-01 | 2025-02-12 | 2024-11-14 | 2024-09-03 | 2024-05-02 | 2024-02-07 | 2023-11-07 | 2023-09-05 | 2023-04-27 | 2023-02-16 |
| Reported EPS | -1 | -0.64 | -1.58 | -0.64 | -1.72 | -2.11 | -2.3 | -1.54 | -2.88 | -2.16 | -1.98 | -3.7 |
| Estimated EPS | -0.28 | -1.31 | -1.51 | -0.93 | -1.49 | -1.46 | -1.5 | -2.03 | -2.38 | -2.59 | -2.66 | -2.56 |
| Surprise | -0.72 | 0.67 | -0.07 | 0.29 | -0.23 | -0.65 | -0.8 | 0.49 | -0.5 | 0.43 | 0.68 | -1.14 |
| Surprise Percentage | -257.1429% | 51.145% | -4.6358% | 31.1828% | -15.4362% | -44.5205% | -53.3333% | 24.1379% | -21.0084% | 16.6023% | 25.5639% | -44.5313% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-02-12 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | 0.1167 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ASND
2025-11-17 21:15:00
Ascendis Pharma A/S announced the publication of pivotal Week 52 results from its ApproaCH Trial of TransCon® CNP (navepegritide) for children with achondroplasia in JAMA Pediatrics. The trial demonstrated significant improvements in annualized growth velocity, lower-limb alignment, body proportionality, and health-related quality of life, with a safety profile similar to placebo. This potential new treatment is currently under review by both the U.S. FDA and European Medicines Agency.
2025-11-17 16:01:00
Ascendis Pharma announced the publication of pivotal Week 52 results from its ApproaCH Trial of TransCon® CNP (navepegritide) in children with achondroplasia in JAMA Pediatrics. The trial showed that TransCon CNP significantly improved annualized growth velocity, body proportionality, and lower-limb alignment, with a safety profile similar to placebo. TransCon CNP is currently under FDA Priority Review with a PDUFA target date of November 30, 2025, and is also under review by the European Medicines Agency.
2025-11-14 08:12:00
Ascendis Pharma A/S (NASDAQ:ASND) reported its Q3 2025 earnings, missing EPS expectations with -€1.17 against a -€0.41 forecast. The company highlighted strong global launches for Eurvipath and Skytrofa, leading to positive operating income and cash flow, and discussed the nearing potential approval of TransCon CNP. Executives also addressed questions regarding patient enrollment, payer approval rates, and commercial strategies for their key products.
2025-11-13 21:03:00
Ascendis Pharma A/S is experiencing a significant surge in stock performance, driven by positive FDA news, strong Q3 financial results including revenues of €213.63M, and optimistic analyst ratings. Despite a reported death linked to one of its drugs, Yorvipath, analysts maintain positive outlooks, emphasizing the drug's benefit-risk balance and the company's strong product pipeline. Ascendis Pharma's strategic product launches and R&D efforts position it for continued growth and market leadership in the biotech sector.
2025-11-02 16:11:26
The human growth hormone market is projected to reach USD 18.75 billion by 2033, growing at a CAGR of 11.90% from USD 7.63 billion in 2025. This growth is driven by increasing R&D investments and rising public awareness of growth hormone deficiency, despite challenges from potential side effects of hormone therapies. North America leads the market, while short-acting growth hormones and growth hormone deficiency applications dominate their respective segments.
2025-11-02 11:35:05
Jefferies analyst Kelly Shi has maintained a Buy rating on Ascendis Pharma A/S (ASND.US) and increased the target price from $233 to $235. According to TipRanks data, the analyst has a 42.3% success rate and an average return of 1.6% over the past year. The information presented is for informational purposes only and does not constitute investment advice.
